JB Chemicals & Pharmaceuticals has reported a subdued set of Q4 FY26 results, with management describing the quarter as a transient but important phase of post-acquisition integration following an operational reset across the business.

 

The company posted revenue of Rs. 904 crore, down 5% year-on-year, while EBITDA stood at Rs. 241 crore, broadly flat. Gross margins remained strong at 70%, with EBITDA margins at 27%. Net profit after tax came in at Rsm 101 crore, while adjusted PAT stood at Rs. 150 crore.

 

Management attributed the muted performance to a series of integration-led changes, including distribution restructuring, portfolio pruning in trade generics, and alignment of sales, credit, and cut-off policies with the parent organisation.

 

“The quarter therefore represents a transient but important phase of integration, with the Company working towards harmonizing operational structures and strengthening the foundation for long-term growth and efficiency.”

 

It also noted that “One-offs in Q4 include distribution network optimisation initiatives undertaken as part of the integration process, discontinuation of low margin portfolio of trade generics business, alignment of trade and sales closing practices with parent entity, and alignment of cut-off policies as part of the post-acquisition integration process, resulting in a timing impact on revenue during the quarter.”

 

Despite headline softness, the India business grew 2% year-on-year to Rs. 526 crore for the quarter and 9% for FY26 to Rs. 2,461 crore. The chronic segment remained a standout, growing 19% versus industry growth of 14%.

 

As per IQVIA MAT March 2026 data, the India business grew 11%, outperforming the broader IPM growth of 10%, while secondary sales also rose 11%.

 

 

International formulations declined 9% in Q4 to Rsm 259 crore, though full-year revenue still grew 2% to Rs. 1,154 crore. Performance was impacted by inventory rationalisation, tighter credit norms post-change in control, and shipping delays caused by container constraints.

 

“Shipment delays due to container constraints in international markets. Some of these shipments particularly to the Middle East remain on hold while others will be shipped during Q1.”

 

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year, while full-year revenue remained flat at Rs. 445 crore. The company also cited reduced customer inventory levels as a drag on growth.

 

Even as revenue softened, profitability metrics remained steady, supported by cost synergies and improved business mix. EBITDA margin expanded to 27%, while gross margins held firm at 70%.

 

“Despite revenue impact in Q4, significant improvement in gross margin and EBITDA margin profile is seen due to cost synergies and improving business mix; further cost synergy execution for the upcoming year remains on track as per guidance.”

 

 

Management reiterated that the current phase reflects temporary integration-related disruption, with performance expected to improve progressively from April onwards.

 

“The Company believes these impacts are temporary in nature and the business performance is expected to progressively improve in the coming quarters, starting from April.”

 

Despite near-term pressure, the company maintained that core business fundamentals remain strong and that alignment with parent-company systems will support longer-term efficiency and growth momentum.